

**Amendments to the Specification:**

Please replace the paragraph beginning at page 11, line 6 with the following amended paragraph:

**Figure 6.** The MS/MS spectra of the two Gas6 peptides bound by MAB WG1. **A.**  $m/z = 1599$ , AVPLSVALVDYHSTK (SEQ. ID. No. 37) and **B.**  $m/z = 1315$ , IAVAGDLFQPER (SEQ. ID. No. 38).

Please replace the paragraph beginning at page 21, line 33 with the following amended paragraph:

As those of skill will appreciate, the present invention includes at least one biologically active antibody of the present invention. Biologically active antibodies have a specific activity at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95%-~~1000%~~ 100% of that of the native (non-synthetic), endogenous or related and known antibody. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity are well known to those of skill in the art.

Please replace the paragraph beginning at page 36, line 35 with the following amended paragraph:

**Example 4: Cloning and Expression in CHO Cells**

Please replace the paragraph beginning at page 30, line 7 with the following amended paragraph:

Methods for engineering or humanizing non-human or human antibodies can also be used and are well known in the art. Generally, a humanized or engineered antibody has one or more amino acid residues from a source which is non-human, e.g., but not limited to mouse, rat, rabbit, non-human primate or other mammal. These human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable, constant

or other domain of a known human sequence. Known human Ig sequences are disclosed, e.g., in a number of public databases such as the NCBI database of the National Institute of Health or publications such as [www.ncbi.nlm.nih.gov/entrez/query.fcgi](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi);  
[www.atcc.org/phage/hdb.html](http://www.atcc.org/phage/hdb.html); [www.seiquest.com/](http://www.seiquest.com/); [www.abcam.com/](http://www.abcam.com/);  
[www.antibodyresource.com/onlinecomp.html](http://www.antibodyresource.com/onlinecomp.html);  
[www.public.iastate.edu/~pedro/research\\_tools.html](http://www.public.iastate.edu/~pedro/research_tools.html); [www.mgen.uni-heidelberg.de/SD/IT/IT.html](http://www.mgen.uni-heidelberg.de/SD/IT/IT.html); [www.whfreeman.com/immunology/CH05/kuby05.htm](http://www.whfreeman.com/immunology/CH05/kuby05.htm);  
[www.library.thinkquest.org/12429/Immune/Antibody.html](http://www.library.thinkquest.org/12429/Immune/Antibody.html);  
[www.hhmi.org/grants/lectures/1996/vlab/](http://www.hhmi.org/grants/lectures/1996/vlab/); [www.path.cam.ac.uk/~mrc7/mikeimages.html](http://www.path.cam.ac.uk/~mrc7/mikeimages.html);  
[www.antibodyresource.com/](http://www.antibodyresource.com/);  
[meb.harvard.edu/BioLinks/Immunology.html](http://meb.harvard.edu/BioLinks/Immunology.html); [www.immunologylink.com/](http://www.immunologylink.com/);  
[pathbox.wustl.edu/~hcenter/index.html](http://pathbox.wustl.edu/~hcenter/index.html); [www.biotech.ufl.edu/~hel/](http://www.biotech.ufl.edu/~hel/);  
[www.pebio.com/pa/340913/340913.html](http://www.pebio.com/pa/340913/340913.html); [www.nal.usda.gov/awic/pubs/antibody/](http://www.nal.usda.gov/awic/pubs/antibody/);  
[www.mchime-u.ac.jp/~yasuhito/Elisa.html](http://www.mchime-u.ac.jp/~yasuhito/Elisa.html); [www.biodesign.com/table.asp](http://www.biodesign.com/table.asp);  
[www.icenet.uk/axp/faes/davies/links.html](http://www.icenet.uk/axp/faes/davies/links.html); [www.biotech.ufl.edu/~fecl/protocol.html](http://www.biotech.ufl.edu/~fecl/protocol.html);  
[www.isac-net.org/sites\\_geo.html](http://www.isac-net.org/sites_geo.html); [aximt1.imt.uni-marburg.de/~rek/AEPStart.html](http://aximt1.imt.uni-marburg.de/~rek/AEPStart.html);  
[baserv.uci.kun.nl/~jraats/links1.html](http://baserv.uci.kun.nl/~jraats/links1.html); [www.recab.uni-hd.de/immuno.bme.nwu.edu/](http://www.recab.uni-hd.de/immuno.bme.nwu.edu/);  
[www.mrc-cpe.cam.ac.uk/imt-doc/public/INTRO.html](http://www.mrc-cpe.cam.ac.uk/imt-doc/public/INTRO.html); [www.ibt.unam.mx/vir/V\\_mice.html](http://www.ibt.unam.mx/vir/V_mice.html);  
[imgt.cnusc.fr:8104/](http://imgt.cnusc.fr:8104/); [www.biochem.ucl.ac.uk/~martin/abs/index.html](http://www.biochem.ucl.ac.uk/~martin/abs/index.html); [antibody.bath.ac.uk/](http://antibody.bath.ac.uk/);  
[abgen.cvm.tamu.edu/lab/wwwabgen.html](http://abgen.cvm.tamu.edu/lab/wwwabgen.html);  
[www.unizh.ch/~honegger/AHOseminar/Slide01.html](http://www.unizh.ch/~honegger/AHOseminar/Slide01.html); [www.cryst.bbk.ac.uk/~ubcg07s/](http://www.cryst.bbk.ac.uk/~ubcg07s/);  
[www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm](http://www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm);  
[www.path.cam.ac.uk/~mrc7/humanisation/TAHHP.html](http://www.path.cam.ac.uk/~mrc7/humanisation/TAHHP.html);  
[www.ibt.unam.mx/vir/structure/stat\\_aim.html](http://www.ibt.unam.mx/vir/structure/stat_aim.html); [www.biosci.missouri.edu/smithgp/index.html](http://www.biosci.missouri.edu/smithgp/index.html);  
[www.cryst.bioc.cam.ac.uk/~finolina/Web\\_pages/Pept/spottech.html](http://www.cryst.bioc.cam.ac.uk/~finolina/Web_pages/Pept/spottech.html);  
[www.jerini.de/fr\\_products.htm](http://www.jerini.de/fr_products.htm); [www.patents.ibm.com/ibm.html](http://www.patents.ibm.com/ibm.html). Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Dept. Health (1983), each entirely incorporated herein by reference.